New Investigations with Lupane Type A-Ring Azepane Triterpenoids for Antimycobacterial Drug Candidate Design.

Journal:
International journal of molecular sciences, Volume: 22, Issue: 22
Published:
November 21, 2021
PMID:
34830423
Authors:
Oxana Kazakova O, Roxana Racoviceanu R, Anastasiya Petrova A, Marius Mioc M, Adrian Militaru A, Lucreția Udrescu L, Mihai Udrescu M, Adrian Voicu A, Jason Cummings J, Gregory Robertson G, Diane J Ordway DJ, Richard A Slayden RA, Codruța Șoica C
Abstract:

Twenty lupane type A-ring azepano-triterpenoids were synthesized from betulin and its related derivatives and their antitubercular activity against , mono-resistant MTB strains, and nontuberculous strains and Mycobacterium were investigated in the framework of AToMIc (Anti-mycobacterial Target or Mechanism Identification Contract) realized by the Division of Microbiology and Infectious Diseases, NIAID, National Institute of Health. Of all the tested triterpenoids, 17 compounds showed antitubercular activity and 6 compounds were highly active on the H37Rv wild strain (with MIC 0.5 µM for compound ), out of which 4 derivatives also emerged as highly active compounds on the three mono-resistant MTB strains. Molecular docking corroborated with a machine learning drug-drug similarity algorithm revealed that azepano-triterpenoids have a rifampicin-like antitubercular activity, with compound scoring the highest as a potential RNAP potential inhibitor. FIC testing demonstrated an additive effect of compound when combined with rifampin, isoniazid and ethambutol. Most compounds were highly active against with compound recording the same MIC value as the control rifampicin (0.0625 µM). The antitubercular ex vivo effectiveness of the tested compounds on THP-1 infected macrophages is correlated with their increased cell permeability. The tested triterpenoids also exhibit low cytotoxicity and do not induce antibacterial resistance in MTB strains.